Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.

Future Oncol · 2025 · PMC11988240 · PMID 40105595

Europe PMC DOI

hedged sentence

0.0523

closest p · 1.0× alpha

0.0523

boldest claim

The sentences

nearly significantp = 0.0523so close (0.05 < p ≤ 0.1)

However, a significantly higher complete response rate was observed for fosnetupitant (74%) than fosaprepitant (67%, p = 0.0450) during the extended overall phase (0–168 hours) and a nearly significant difference was seen between fosnetupitant (87%) and fosaprepitant (82%, p = 0.0523) during the long-delayed phase (120–168 hours) [ 59 , 71 ].

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.